Product Information
VOQUEZNA TRIPLE PAK is a brand product labeled by Phathom Pharmaceuticals Inc., priced at $7.5166 per EA under NDC 81520025514. Its NADAC has been published 118 times since May 22, 2024.
FDA first approved this application on May 3, 2022.
Manufacturer
Phathom Pharmaceuticals Inc.NDC
81520025514
Classification
Brand
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
New Drug (NDA)
FDA Application
NDA215152FDA Approved
5/3/2022
On Market Since
11/8/2023
Price Statistics
The NADAC for VOQUEZNA TRIPLE PAK has been published 118 times since May 22, 2024, and over the history we have for it it has risen 8.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.5166 per EA |
|---|---|
| All-time high | $7.5166 (Aug 19, 2026) |
| All-time low | $6.9193 (Nov 20, 2024) |
| 52-week high | $7.5166 |
| 52-week low | $7.2705 |
| Median price | $7.2705 |
| Average price | $7.2433 |
| Largest weekly change | +5.0% (Jan 8, 2025) |
| Weeks tracked | 118 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the vonoprazan fumarate, amoxicillin and clarithromycin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VOQUEZNA TRIPLE PAK?
The current National Average Drug Acquisition Cost (NADAC) for VOQUEZNA TRIPLE PAK, manufactured by Phathom Pharmaceuticals Inc., is $7.5166 per EA (NDC 81520025514), effective Aug 19, 2026.
How has the price of VOQUEZNA TRIPLE PAK changed over time?
Over the history we have for it, the NADAC for VOQUEZNA TRIPLE PAK has risen 8.4%. It has been tracked across 118 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for VOQUEZNA TRIPLE PAK?
Since May 22, 2024, the NADAC for VOQUEZNA TRIPLE PAK has ranged from a low of $6.9193 (Nov 20, 2024) to a high of $7.5166 (Aug 19, 2026), with a median of $7.2705 per EA.
Are there cheaper alternatives to VOQUEZNA TRIPLE PAK?
No other NADAC-published product currently shares the active ingredient and strength of VOQUEZNA TRIPLE PAK in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VOQUEZNA TRIPLE PAK?
VOQUEZNA TRIPLE PAK (NDC 81520025514) is labeled by Phathom Pharmaceuticals Inc., and CMS classifies it as a brand product.